Top Biopharma Deal April 2021: CRISPR – Vertex for CTX001 for Sickle Cell Disease and Transfusion-Dependent Beta-Thalassemia
Highlighted Deal Financial Comps
Total Deal Value:
Cost & Profit Split:
- CRISPR Therapeutics and Vertex Pharmaceuticals amended their 2015 deal to develop and commercialize gene editing therapies where Vertex had an exclusive option to license up to 6 targets.
- This expansion is for CTX001, a CRISPR/Cas9-based gene editing therapy for severe sickle cell disease and transfusion-dependent beta-thalassemia.
- Vertex will lead global development, manufacturing, and commercialization and will be responsible for 60% of program costs with 60% of profits, a 10% increase over its original agreement.
- CRISPR will be responsible for 40% of costs and will receive 40% of profits.
- CRISPR will receive $900M up front and is eligible for up to $200M in milestones upon the first regulatory approval.
Congrats to CRISPR and Vertex for landing the DealForma April 2021 Top Biopharma Deal of the Month. The Deal of the Month for March 2021 was the Debiopharm – Merck KGaA deal for Xevinapant. Read about it here.
DealForma’s Deal of the Month selection is based on the largest disclosed upfront cash and equity total in partnership deals involving R&D as announced in the month prior to this article. Data for this analysis was compiled using the DealForma biopharma deals database. All data are based on publicly disclosed figures and deal terms.
We invite you to answer interesting questions on biopharma business development and licensing using our data and carefully curated profiles on deals, pipelines, companies, funding, and business executives by visiting dealforma.com to schedule your personalized demo.
Drug Sales Figures